PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
Who is this study for? Patients with Chronic Pain
What treatments are being studied? Cannabidiol
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: f
View:
• Subject has provided informed consent
• Subject is 21 or older
• Subject is fluent in English
• Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.
Locations
United States
Massachusetts
McLean Hospital
RECRUITING
Belmont
Contact Information
Primary
Staci Gruber, Ph.D.
gruber@mclean.harvard.edu
617-855-2762
Backup
Rosie Smith, M.S.
cbdstudy@mclean.harvard.edu
617-855-3338
Time Frame
Start Date: 2024-06-27
Estimated Completion Date: 2026-09
Participants
Target number of participants: 25
Treatments
Experimental: Cannabidiol Treatment Arm
High-CBD sublingual product administered three times daily for the treatment period.
Placebo_comparator: Placebo Treatment Arm
Placebo sublingual product administered three times daily for the treatment period.
Related Therapeutic Areas
Sponsors
Leads: Staci Gruber, Ph.D.
Collaborators: Etheridge Foundation